NAS10029,709+0.19%S&P7,737+0.19%GOLD$4,053−0.54%BTC$80,942+0.17%VIX17.29−1.31%latest tape · as of 18:04 UTC
The Screen · Consumer Defensive · Household & Personal Products
Interparfums, Inc.
IPAR · Nasdaq · USD · Market cap $3.6B · 662 employees
Interparfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.07, read 2026-10-27
Ethical passes the values gate
Price115.19 USD
Fair value89.13
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Markdown113.20+1.8% to today Accumulation gives way to Markdown
2026-10-11Read Accumulation113.95+1.1% to today ✓Distribution gives way to Accumulation
2026-09-02Read Distribution116.67-1.3% to today ✓Markup gives way to Distribution after a 15% rise in 9 weeks
2026-07-02Read Markup101.78+13.2% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Interparfums, Inc. holds its Markdown at $115.19. The statistical read favours the buyers, held for 367 days.
As held on the ledger · 2026-10-27
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 367 days
Price at the screen
$115.19
Valuation
21.60 trailing · 21.76 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.18
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
13.10%
Below 33%
Interest-bearing debt is just 13.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
8.65%
Below 33%
Cash held in interest-bearing accounts and securities is 8.6% of assets, under the one-third limit.
Pass
Receivables
30.20%
Below 49%
Money owed to the company is 30.2% of assets, under the 49% limit.
Pass
Revenue purity
0.26%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Interparfums, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IPAR's ethical verdict changes
Today IPAR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 21.3% above the base estimate.
Third-party analyst targets: 6 covering, consensus None. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Perfume Bottles Sell But Shares Do Not
Every time a shopper picks up a licensed fragrance in a department store or duty free, Interparfums earns a slice of that sale through its European and US operations. The business runs at a solid 20 percent return on equity and clears an 11 percent profit margin, yet revenue is growing just 2 percent a year. At 22 times forward earnings the shares sit well above our fair value of 89 dollars, leaving a negative margin of safety and no opportunity rating.
We pass for the simple reason that price matters. The market has bid the stock to 123 dollars on a strong buy consensus, but that valuation leaves no room for the modest growth on offer. Low top line expansion in a competitive licensing business rarely justifies such multiples for long.
Currency moves, fashion shifts and the loss of key fragrance contracts remain real threats that could compress margins further. The ethical screen is clear, yet the numbers still point to an expensive defensive name rather than a bargain.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IPAR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown · changed$113.20+0.0%Entry 10
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$113.20-1.7%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
2026-10-18Accumulation$115.11+1.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
2026-10-02Distribution$112.76-3.4%Entry 6
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
2026-08-02Markup$123.23+21.1%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
2026-07-18Markup$101.78+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
2026-07-03Markup$101.78+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$101.78Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
